Recruiting
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924· Phase 3· Canadian Cancer Trials Group· Source
Contact: Lorin Dodbiba (principal investigator)
Recruiting
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485· Phase 3· Canadian Cancer Trials Group· Source
Contact: Terry M. Zwiep (principal investigator)
Recruiting
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
NCT06235697· Phase 3· Canadian Cancer Trials Group· Source
Contact: Lucas C. Mendez (principal investigator)
Recruiting
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241· Phase 2/3· National Cancer Institute (NCI)· Source
Contact: Melissa Huynh (principal investigator)
Recruiting
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
NCT05773274· Phase 2· National Cancer Institute (NCI)· Source
Contact: David Laidley (principal investigator)
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· Phase 3· NRG Oncology· Source
Contact: Veera Durga S. Panuganty (principal investigator)
Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Hamid Mithoowani (principal investigator)
Active, not recruiting
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
NCT05876754· Phase 3· Servier Affaires Médicales· Source
Recruiting
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169· Phase 2/3· NRG Oncology· Source
Contact: Elena V. Tsvetkova (principal investigator)
Active, not recruiting
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
NCT04663997· Phase 2· Canadian Cancer Trials Group· Source
Recruiting
Standard Versus Radiobiologically-Guided Dose Selected SBRT in Liver Cancer
NCT04745390· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source
Contact: Robin Sachdeva, PhD
Active, not recruiting
Three Fraction Radiation to Induce Immuno-Oncologic Response
NCT03978663· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source
Active, not recruiting
A Study of miRNA 371 in Patients With Germ Cell Tumors
NCT04435756· SWOG Cancer Research Network· Source
Recruiting
Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma
NCT04220749· Phase 2· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source
Contact: Danielle MacNeil, MD
Active, not recruiting
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NCT04068103· Phase 2/3· NRG Oncology· Source
Active, not recruiting
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
NCT03768570· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
NCT03997643· Phase 2· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source
Active, not recruiting
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)
NCT03772899· Phase 1· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source
Active, not recruiting
CFI-400945 in Patients With Advanced/Metastatic Breast Cancer
NCT03624543· Phase 2· Canadian Cancer Trials Group· Source
Recruiting
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
NCT03550391· Phase 3· Canadian Cancer Trials Group· Source
Contact: Melody Qu (principal investigator)
Recruiting
Low-Dose Weekly vs High-Dose Cisplatin
NCT03649048· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source
Contact: Sara Kuruvilla, MD
Active, not recruiting
Prostate Cancer Biomarker Enrichment and Treatment Selection
NCT03385655· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
NCT03410615· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
Primary Radiotherapy Versus Primary Surgery for HPV-Associated Oropharyngeal Cancer
NCT03210103· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source
Active, not recruiting
SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial
NCT03306680· Phase 1· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source
Active, not recruiting
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
NCT03180268· Phase 3· NRG Oncology· Source
Active, not recruiting
Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02905318· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
NCT03055013· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT03137771· Phase 2· NRG Oncology· Source
Active, not recruiting
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266· Phase 2/3· National Cancer Institute (NCI)· Source
Active, not recruiting
Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy
NCT02788461· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source
Active, not recruiting
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02446600· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT02506153· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Economic Analysis of Alliance A041202 CLL Study
NCT02414022· Canadian Cancer Trials Group· Source
Active, not recruiting
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT02107703· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02101775· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
NCT02446405· Phase 3· University of Sydney· Source
Active, not recruiting
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01886872· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
NCT01396408· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
NCT01368588· Phase 3· Radiation Therapy Oncology Group· Source
Active, not recruiting
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
NCT01220583· Phase 2· Radiation Therapy Oncology Group· Source
Active, not recruiting
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
NCT00956007· Phase 3· Radiation Therapy Oncology Group· Source
Active, not recruiting
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
NCT01924819· Phase 2/3· Australasian Gastro-Intestinal Trials Group· Source
Active, not recruiting
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
NCT00499330· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
NCT00070499· Phase 2· National Cancer Institute (NCI)· Source